IFNA1 and Hypocalcemia: (ii) Use biomarkers with diagnostic and prognostic leverage: 21-hydroxylase for AAD; neutralizing anti-IFN for APS-1; anti-CaSR for unexplained hypocalcemia; DNAm signatures for risk stratification in AITD (pending validation).